Video
Author(s):
Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).
Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, advisory committee of the Association of Community Cancer Centers, discusses the management of immune-related adverse events (irAEs).
An initiative is looking at the management of these AEs. The idea of the workshop is to help offer guidance and educational initiatives with the intention of improving patient outcomes following immunotherapy—generally with checkpoint inhibitors as they are used most commonly, says Zibelman.
The goal of a workshop being conducted by the Association of Community Cancer Centers Immuno-Oncology Institute is to provide interventions of education both to patients, as well as to staff and faculty, to improve their understanding of the relationship between AEs and patient outcomes. As part of the workshop, 2 cancer centers have been selected to participate with the program. This will offer education to patients and physicians alike, says Zibelman.
Zibelman explains that this will take the form of tumor boards. Members of the committee will monitor the centers to see whether there are improvements in how physicians manage their patients, how they recognize these side effects, and how they treat them. The ultimate goal is to show that these interventions can make a difference and can be used and repurposed for other organizations as well.
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
2 Commerce Drive
Cranbury, NJ 08512